Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy</td>
<td>C50</td>
<td>00377a</td>
<td>Cyclophosphamide: CDS Methotrexate and 5-Fluorouracil: Hospital</td>
</tr>
<tr>
<td>Metastatic breast carcinoma</td>
<td>C50</td>
<td>00377b</td>
<td></td>
</tr>
</tbody>
</table>

TREATMENT:
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Adjuvant treatment: Treatment is administered for 6 cycles
Metastatic: Treatment is administered until disease progression or unacceptable toxicity develops

<table>
<thead>
<tr>
<th>Admin Order</th>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1 and 8</td>
<td>5-Fluorouracil</td>
<td>600mg/m²</td>
<td>IV bolus</td>
<td>N/A</td>
<td>Every 28 days</td>
</tr>
<tr>
<td>2</td>
<td>1 and 8</td>
<td>Methotrexate</td>
<td>40mg/m²</td>
<td>IV bolus</td>
<td>N/A</td>
<td>Every 28 days</td>
</tr>
<tr>
<td>3</td>
<td>1 to 14 inclusive</td>
<td>Cyclophosphamide</td>
<td>100mg/m²</td>
<td>PO one hour before food or on an empty stomach</td>
<td>N/A</td>
<td>Every 28 days</td>
</tr>
</tbody>
</table>

Cyclophosphamide is available as 50mg tablets. Tablets should be swallowed whole with a glass of water.

*See dose modifications section for patients with identified partial DPD deficiency

ELIGIBILITY:
- Indications as above
- ECOG status 0-2
- Adequate haematological, renal and liver status

EXCLUSIONS:
- Hypersensitivity to cyclophosphamide, methotrexate, fluorouracil or any of the excipients.
- Pregnancy
- Lactation
- Known complete DPD deficiency
PREScriptive authority: The treatment plan must be initiated by a consultant medical oncologist.

Tests:

Baseline tests:
- FBC, renal and liver profile
- DPD testing prior to first treatment with 5-Fluorouracil using phenotype and/or genotype testing unless patient has been previously tested

Regular tests:
- FBC, renal and liver prior to each cycle

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising consultant.

Dose modifications:
- Consider a reduced starting dose in patients with identified partial DPD deficiency.
  - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a consultant.

Haematological:
Table 1: Dose modification of CMF in haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x10⁹/L)</th>
<th>Platelets (x10⁹/L)</th>
<th>Recommended Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;1.5</td>
<td>Or &gt;90</td>
<td>100%</td>
</tr>
<tr>
<td>1-1.49</td>
<td>70-89</td>
<td>75%</td>
</tr>
<tr>
<td>&lt;1</td>
<td>&lt;70</td>
<td>Delay</td>
</tr>
</tbody>
</table>
# Renal and Hepatic Impairment:

## Table 2: Dose modification of CMF in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cyclophosphamide</strong></td>
<td>Cr Cl (ml/min)</td>
<td>Dose</td>
</tr>
<tr>
<td>&gt;20</td>
<td>100%</td>
<td>Severe impairment: Clinical Decision</td>
</tr>
<tr>
<td>10-20</td>
<td>75%</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>50%</td>
<td></td>
</tr>
<tr>
<td><strong>Methotrexate</strong></td>
<td>CrCl (ml/min)</td>
<td>Dose</td>
</tr>
<tr>
<td>≥50</td>
<td>100%</td>
<td>&lt;50</td>
</tr>
<tr>
<td>20-50</td>
<td>50%</td>
<td>51-85</td>
</tr>
<tr>
<td>&lt;20</td>
<td>Not recommended. If unavoidable consider haemodialysis</td>
<td>&gt;85</td>
</tr>
<tr>
<td><strong>5-Fluorouracil</strong></td>
<td>Consider dose reduction in severe renal impairment only</td>
<td>Bilirubin (micromol/L)</td>
</tr>
<tr>
<td>&lt;85</td>
<td>&lt;180</td>
<td>100%</td>
</tr>
<tr>
<td>&gt;85</td>
<td>or</td>
<td>&gt;180</td>
</tr>
</tbody>
</table>

**Clinical decision:**
- Moderate hepatic impairment; reduce initial dose by 1/3.
- Severe hepatic impairment; reduce initial dose by 1/2.
- Increase dose if no toxicity.

## SUPPORTIVE CARE:

### EMETOGENIC POTENTIAL:

- 5-fluorouracil: Low (Refer to local policy).
- Methotrexate: Low (Refer to local policy).
- Cyclophosphamide: Moderate to high (Refer to local policy).

## PREMEDICATIONS:

Not usually required

## OTHER SUPPORTIVE CARE:

Patients should have an increased fluid intake of 2-3 litres on day 1 and day 8 to prevent haemorrhagic cystitis with cyclophosphamide.
ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pleural effusion or ascites**: Methotrexate should be used with caution in patients with pleural effusion or ascites, as methotrexate may accumulate in third space fluid compartments.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency**: DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS)**, also known as palmar-plantar erythrodysaesthesia (PPE) has been reported as an unusual complication of high dose bolus or protracted continuous therapy for 5-fluorouracil.
- **Myocardial ischaemia and angina**: Cardiotoxicity is a serious complication during treatment with fluorouracil. Patients, especially those with a prior history of cardiac disease or other risk factors, treated with fluorouracil, should be carefully monitored during therapy.

DRUG INTERACTIONS:

- CYP3A inhibitors decrease the conversion of cyclophosphamide to both its active and inactive metabolites. Patients should also be counselled with regard to consumption of grapefruit juice.
- CYP3A inducers may also increase the conversion of cyclophosphamide to both its active and inactive metabolites.
- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probencid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Fluorouracil significantly reduces the metabolism of warfarin. INR and signs of bleeding should be monitored regularly and dose of warfarin adjusted as required.
- Concurrent administration of fluorouracil and phenytoin may result in increased serum levels of phenytoin.
- Caution should be taken when using fluorouracil in conjunction with medications which may affect dihydropyrimidine dehydrogenase activity.
• Fluorouracil is contraindicated in combination with brivudin, sorivudin and analogues as these are potent inhibitors of the 5-FU-metabolising enzyme dihydropyrimidine dehydrogenase (DPD).
• Current drug interaction databases should be consulted for more information.

REFERENCES:

Version Date Amendment Approved By
1 1/12/2016 Updated to new NCCP template Standardised dosing in renal and hepatic impairment Prof Maccon Keane
2 26/11/2018 Updated exclusions, dose modifications for hepatic impairment and drug interactions. Prof Maccon Keane
3 27/12/2019 Reviewed. Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia Prof Maccon Keane
4 25/8/2020

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

NCCP Regimen: CMF (Oral)
Tumour Group: Breast
NCCP Regimen Code: 00377
Published: 01/12/2016
Version number: 5
Review: 23/09/2025
ISM0 Contributor: Prof Maccon Keane
Page 5 of 6
NCCP Chemotherapy Regimen

NCCP Regimen: CMF (Oral)  
Published: 01/12/2016  
Review: 23/09/2025  
Version number: 5  
Tumour Group: Breast  
NCCP Regimen Code: 00377  
ISM0 Contributor: Prof Maccon Keane  

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens.